Design Therapeutics Shares Jump 27% on Friedreich’s Ataxia Trial Gains
Design Therapeutics shares jumped 27% after the four-week Phase 1/2 RESTORE-FA trial in 16 Friedreich ataxia patients showed dose-dependent improvements, including a 6.4-point average mFARS increase and 2.7-point stability score gain at 1 mpk. Frataxin mRNA rose 65% at the highest dose, and no serious adverse events occurred.
1. Stock Reaction and Overview
Shares of Design Therapeutics soared 27% on Monday following release of four-week RESTORE-FA Phase 1/2 data demonstrating dose-dependent clinical and biomarker improvements in Friedreich ataxia patients.
2. Clinical Efficacy Results
The study enrolled 16 patients receiving weekly IV doses of DT-216P2 at 0.1, 0.3, 0.6 and 1 mpk, with the 1 mpk cohort showing mean modified Friedreich’s Ataxia Rating Scale improvements of 6.4 points and Upright Stability Score gains of 2.7 points after four weeks.
3. Biomarker and Mechanistic Findings
Whole blood frataxin (FXN) mRNA increased by 65% from baseline at the 1 mpk dose, and dose-dependent rises in endogenous frataxin protein and mRNA levels were observed in both blood and affected muscle tissue assays.
4. Safety Profile and Next Steps
DT-216P2 was generally well tolerated, with only mild-to-moderate transient alanine transaminase elevations in three patients and no serious adverse events; Design Therapeutics plans to outline its registrational pathway during the fourth quarter of 2026.